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EXTENDED REPORT
How common is clinically inactive disease
in a prospective cohort of patients with juvenile
idiopathic arthritis? The importance of definition
Stephanie J W Shoop-Worrall,1,2 Suzanne M M Verstappen,1 Eileen Baildam,3
Alice Chieng,4 Joyce Davidson,5,6 Helen Foster,7,8 Yiannis Ioannou,9 Flora McErlane,7
Lucy R Wedderburn,9,10 Wendy Thomson,2,11 Kimme L Hyrich1,2
ABSTRACT
Objectives Many criteria for clinically inactive disease
(CID) and minimal disease activity (MDA) have been
proposed for juvenile idiopathic arthritis ( JIA). It is not
known to what degree each of these criteria overlap
within a single patient cohort. This study aimed to
compare the frequency of MDA and CID across different
criteria in a cohort of children with JIA at 1 year
following presentation.
Methods The Childhood Arthritis Prospective Study
recruits children at initial presentation to paediatric or
adolescent rheumatology in seven UK centres. Children
recruited between October 2001 and December 2013
were included. The proportions of children with CID and
MDA at 1 year were calculated using four investigator-
defined and eight published composite criteria. Missing
data were accounted for using multiple imputation under
different assumptions.
Results In a cohort of 1415 children and adolescents,
67% patients had no active joints at 1 year. Between
48% and 61% achieved MDA and between 25% and
38% achieved CID using published criteria. Overlap
between criteria varied. Of 922 patients in MDA by
either the original composite criteria, Juvenile Arthritis
Disease Activity Score ( JADAS) or clinical JADAS cut-offs,
68% were classified as in MDA by all 3 criteria.
Similarly, 44% of 633 children with CID defined by
either Wallace’s preliminary criteria or the JADAS cut-off
were in CID according to both criteria.
Conclusions In a large JIA prospective inception
cohort, a majority of patients have evidence of persistent
disease activity after 1 year. Published criteria to capture
MDA and CID do not always identify the same groups of
patients. This has significant implications when defining
and applying treat-to-target strategies.
INTRODUCTION
Juvenile idiopathic arthritis ( JIA) represents the
most common inflammatory rheumatic disease of
childhood.1 To minimise pain and disability asso-
ciated with active disease, one goal for all children
with JIA is clinically inactive disease (CID),
meaning absence of active inflammation.2
However, CID is not always achievable and a more
realistic target may be minimal disease activity
(MDA), meaning limited evidence of active inflam-
mation.3 Defining either of these states in such a
heterogeneous disease is challenging; there is no
single diagnostic test for either state and as such
multiple criteria have been proposed.
Simple clinical criteria for CID include no active
joints or a score of zero on the physician (PGA) or
parental (PGE) global evaluation. These single
targets are easy to apply in clinical practice as part
of the core outcome criteria for JIA.4 However,
each alone may not capture the full spectrum of
disease. Composite disease activity scores are more
precise than their individual components, capturing
multiple domains of disease activity and potentially
increasing the statistical power of clinical trials.5
Over the past 15 years, a number of composite cri-
teria have been proposed and variably validated in
JIA patient populations. These include Wallace’s
preliminary criteria for CID and remission on and
off medication,2 the Juvenile Arthritis Disease
Activity Score ( JADAS) and clinical JADAS
(cJADAS) cut-offs for MDA, CID and remission6 7
and the American College of Rheumatology (ACR)
preliminary criteria for CID8 (table 1).
The aim of developing criteria for CID and
MDA has been to better define the states of low
disease activity as well as standardise outcome cri-
teria across clinical trials and observational
research.2 However, differences in patients identi-
fied by each set of criteria may contribute to the
large variation in CID achievement described
between cohorts observed in the literature.9 One
study compared the frequency of CID according to
a modified ACR preliminary criteria8 against
achieving no active joints or zero on the PGA, PGE
or child global assessments of disease activity.
Within this single population, achievement of CID
according to each set of criteria ranged from 19%
to 68%.10 None of these single or modified com-
posite criteria used in the study described has been
validated in JIA and to date, no studies have dir-
ectly compared published criteria within a single
population to understand if they define similar
groups of children.
Multiple high-quality studies support the efficacy
of accelerated or targeted early treatment pathways
in adult inflammatory arthritis (particularly
rheumatoid arthritis (RA)).11–14 Treat-to-target
approaches should lead to similar improvements in
clinical outcomes for patients with JIA, but require
valid, feasible and consistent treatment targets
across different studies.
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This study aims to apply single and published composite cri-
teria for CID and MDA in a single patient population at a
common time point: 1 year following initial presentation to
rheumatology. The proportions of children reaching these states
could then be compared between criteria of CID and MDA.
Specifically, the study objectives are to (1) estimate the frequency
of CID and MDA at 1 year following initial presentation; (2)
investigate the differences in achievement of these disease states
across International League of Associations for Rheumatology
(ILAR) subtypes and (3) investigate if similar groups of children
are captured by the different CID/MDA criteria.
METHODS
Study population
Children and young people were participants in the Childhood
Arthritis Prospective Study (CAPS), a UK multicentre inception
cohort established in 2001. Details of this cohort have been
described previously.16 To date, the cohort exceeds 1500
patients with childhood-onset inflammatory arthritis. CAPS was
approved by the Northwest Multicentre Research Ethics
Committee and written consent from parents/guardians was
attained for all participants. Where possible, children also pro-
vided assent.
Patients were included in the current study if they had a phys-
ician diagnosis of JIA and had been recruited to the cohort
before December 2013, to allow at least 1 year of follow-up.
Prevalent cases and children with no returned study report
forms were excluded.
Data collection
The baseline date was that of first presentation to paediatric or
adolescent rheumatology in one of seven centres in the UK.
Baseline and 1-year follow-up data were collected from medical
case notes, nurse and parent/patient questionnaires. Age and
gender were recorded at baseline. Data from medical case notes
included rheumatological diagnosis and ILAR subtype. ILAR
category was defined using study data available at 1 year to
allow children to ‘settle’ into a category. If ILAR category was
missing at 1 year, the most recent previously collected ILAR cat-
egory was used. Data from case notes also included number of
active and limited joints (maximum 71), a 10 cm visual analogue
scale (VAS) assessing physician’s global assessment of disease
activity, extra-articular disease features, results of laboratory
investigations including erythrocyte sedimentation rate (ESR)
(mm/hour) and C reactive protein (mg/L) and medication details
including both antirheumatic and other therapeutics. Parent
questionnaires included a Childhood Health Assessment
Questionnaire, and two 10 cm VAS measures for pain and well-
being, respectively. Young people over the age of 11 have the
option to self-report.
Outcomes of CID and MDA
Outcomes comprising a single criterion included no active joints
and zero on the PGA or PGE. Published composite outcomes
for the current analysis included CID according to the Wallace’s
preliminary criteria,2 JADAS6 and cJADAS7 and MDA according
to the JADAS,6 cJADAS7 and the original Magni-Manzoni cri-
teria3 (table 1). The sets of criteria were applied in full across all
ILAR subtypes. As CAPS did not capture daily morning stiffness
over most of the period of recruitment to this study, the ACR
preliminary criteria for CID8 were not applied.
Statistical analyses
All outcomes were calculated from extracted data items at the
1-year follow-up visit. The frequency and proportion of out-
comes in all patients and within ILAR subtypes were reported.
In addition, the overlap between patient groups identified by
multiple outcomes was explored.
The primary analysis assumed that some data were missing
(table 3) in a ‘missing-not-at-random’ mechanism. Children with
missing data were split into six groups: those (1) discharged
‘well’, (2) discharged following repeat non-attendance, (3) trans-
ferred to other clinics, (4) moved home address or unknown
reason for discharge, (5) lost to follow-up in CAPS and (6)
follow-up form completed but with incomplete data. The fol-
lowing assumptions were made regarding these groups: patients
Table 1 Published CID and minimal disease activity criteria for JIA
Components included
Requirement for classification of CID or MDACriteria AJC PGA PGE ESR/CRP
Systemic
features Uveitis
Morning
stiffness
Composite CID criteria
Wallace’s preliminary criteria2 ✓ ✓ ✓ ✓ ✓* Normal ESR/CRP and all other values at zero or not present
ACR preliminary criteria8 ✓ ✓ ✓ ✓ ✓† ✓ Normal ESR/CRP, morning stiffness ≤15 min and all other values at
zero or not present
JADAS6 ✓ ✓ ✓ ✓ JADAS ≤1
cJADAS7 ✓ ✓ ✓ cJADAS ≤1
Composite MDA criteria
MDA (Magni-Manzoni)3 ✓ ✓ ✓‡ Persistent oligoarticular: AJC=0, PGA ≤2.5
Extended oligoarticular, polyarticular and systemic JIA: AJC ≤1, PGA
≤3.4, PGE ≤2.1
JADAS6 ✓ ✓ ✓ ✓ Oligoarticular course: JADAS ≤2.0
Polyarticular course: JADAS ≤3.8
cJADAS7 ✓ ✓ ✓ Oligoarticular course: cJADAS ≤1.5
Polyarticular course: cJADAS ≤2.5
*Inactive uveitis was not defined.
†Inactive uveitis as defined by the Standardization of Uveitis Nomenclature working group.15
‡Not required for persistent oligoarticular JIA.
ACR, American College of Rheumatology; AJC, active joint count; CID, clinically inactive disease; cJADAS, clinical JADAS; CRP, C reactive protein; ESR, erythrocyte sedimentation rate;
JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic arthritis; MDA, minimal disease activity; PGA, Physician’s global assessment of disease activity; PGE, parental/child
global evaluation of disease activity.
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were in CID according to all outcome criteria (groups one, two,
five and three if transferred to adult services) or patients had
normal laboratory criteria with other missing data missing at
random (MAR) (group six). Unless assumed ‘well’, all other
missing data were imputed via multiple imputation over 20
iterations assuming data MAR.
Secondary analyses included a complete case analysis as well
as a most extreme scenario analysis, which assumed all children
with missing data or forms were either entirely in active disease
or entirely in CID/MDA for each set of criteria.
RESULTS
Patient cohort
Up to December 2013, 1510 patients had been recruited to
CAPS. Of these, 95 were excluded (60 were not diagnosed with
JIA, 3 were prevalent cases and 32 had no available data),
leaving 1415 children for analysis.
Sixty-five per cent of children were female and median age at
first presentation was 8 years (IQR 3.5–12 years). The most
common ILAR subtypes were oligoarticular (50%) and rheuma-
toid factor (RF)-negative polyarticular JIA (21%) (table 2).
Median baseline active joint count was two (IQR 1–6) with
median physician global assessment at 2.9 cm (IQR 1.5–5.0)
(table 2).
Achievement of CID or MDA
The 1-year follow-up form was not completed in 85 children.
Fifty-nine had been discharged from rheumatology within the
first year, including 24 who had been discharged ‘well’. Others
had moved to another paediatric or adolescent clinic (n=11),
moved to adult services (n=11) failed to attend (n=30) or were
lost to follow-up (n=9). These patients did not differ signifi-
cantly at baseline from those with 1-year data available, except
for PGA score (available median PGA 2.9 cm, IQR 1.6–5.1,
missing median PGA 2.0 cm, IQR 1.1–3.1, p=0.004).
Overall, 76% (95% CI 73 to 79) of patients achieved CID or
MDA according to at least one set of criteria, with estimates
ranging from 25% using Wallace’s preliminary criteria to 67% if
only an active joint count was used. Using composite criteria,
fewer children achieved CID (range 30%–38%) compared with
MDA (range 48%–61%) (table 3). Imputed estimates consist-
ently exceeded those from complete case analysis (table 3).
Table 2 Baseline and 1 year characteristics of the cohort
Characteristic
No. of patients with
available baseline data (%)
N (%) or median
(IQR) at baseline
No. of patients with
available 1-year data (%)
N (%) or median
(IQR) at 1 year
Female 1415 (100) 917 (65)
White or Caucasian 1380 (98) 1238 (90)
Age at onset (years) 1396 (99) 6.6 (2.7, 11)
Age at first presentation (years) 1409 (100) 7.7 (3.5, 12)
Symptom duration at diagnosis (months) 1391 (98) 5.4 (2.8, 12)
ILAR subtype 1415 (100)
Systemic 96 (6.7)
Oligoarticular 707 (50)
RF− polyarticular 292 (21)
RF+ polyarticular 49 (3.5)
Enthesitis-related 77 (5.4)
Psoriatic 97 (6.9)
Undifferentiated 97 (6.9)
Score components
Active joint count 1269 (90) 2.0 (1.0, 5.0) 1000 (71) 0 (0, 1)
Limited joint count 1269 (90) 1.0 (1.0, 3.0) 1000 (71) 0 (0, 1)
CHAQ score 972 (69) 0.8 (0.1, 1.4) 936 (66) 0.3 (0.0, 0.9)
PGA score (cm) 939 (66) 2.9 (1.5, 5.0) 819 (58) 0.5 (0.0, 1.8)
PGE score (cm) 936 (66) 2.3 (0.5, 5.0) 928 (66) 0.6 (0.1, 2.9)
ESR (mm/hour) 889 (63) 21 (7, 49) 269 (19) 8 (4, 19)
Normal ESR (<20 mm/hour) 889 (63) 441 (50) 269 (19) 212 (79)
CRP (mg/L) 844 (60) 7.0 (4.0, 27) 238 (17) 4 (3, 7)
Normal CRP (dependent on hospital assay) 844 (63) 482 (57) 238 (19) 202 (85)
Diagnosis of uveitis 294 (21) 11 (3.7) 252 (18) 20 (7.9)
Systemic features present (systemic JIA only) 94 (98) 89 (95) 70 (73) 39 (56)
Treatments in the first year 1415 (100)
NSAID 1040 (73)
Steroid* 1050 (74)
DMARD 670 (47)
Biological 115 (8)
Data are presented as n (%) or median (IQR) where appropriate.
*Steroids administered orally/intravenous/intra-articular.
CHAQ, Childhood Health Assessment Questionnaire; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; ILAR, International
League of Associations for Rheumatology; JIA, juvenile idiopathic arthritis; NSAID, non-steroidal anti-inflammatory drug; PGA, physician global assessment of disease activity; PGE,
parental global evaluation of disease activity; RF, rheumatoid factor.
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Estimates of CID across criteria
At 1 year following initial presentation to rheumatology, 42%
(95% CI 38% to 45%) of patients satisfied at least one of the
composite criteria for CID. This is in contrast with 67% (95%
CI 64% to 69%) that had achieved an active joint count of zero.
A third of children had no active joints, but did not achieve a
score of zero on the PGA (33%). Rarely a child with active
joints was scored at zero on the PGA (4%). In these few cases,
children had only one active joint and appeared well on other
disease variables (table 4). Physicians and parents appeared to
score differently with only 35% overlap in patients scoring zero
on both the PGA and PGE (figure 1A). The JADAS and cJADAS
criteria, which include a mixture of physician and
parent-assessed measures, had a high degree of overlap (almost
100%) and both identified 38% of children as in CID at 1 year
(table 3 and figure 1B). Discrepancies between these two groups
were driven by ESR, with patients (n=3) in CID only on the
cJADAS with median 42 mm/hour ESR (IQR 34–65 mm/hour),
compared with 6 mm/hour (IQR 2–11 mm/hour) for those in
CID on both criteria (table 4).
Fewer patients achieved CID on Wallace’s preliminary criteria
(25%, contains only physician-assessed components) compared
with the JADAS criteria (38%, contains both physician and
parent-assessed components). In accordance, there was only a
44% overlap in the patients identified in CID by these criteria
(figure 1C). Where discordances existed between patients
defined as in CID on the Wallace’s preliminary criteria only or
the JADAS10 only, large differences in the PGE (median 2.7
and 0.0 cm, respectively) were evident. However, patients in
CID on the cJADAS had median PGA of 0.2 cm, highlighting
the requirement of an absolute cut-off of 0 cm required for the
Wallace’s preliminary criteria. In addition, 4% of patients with
systemic JIA in CID on the JADAS10 were recorded as having
had active systemic features (table 4). There were no differences
in active joint count or ESR between these groups.
Estimates of MDA across criteria
At 1 year following presentation, 65% (95% CI 62% to 68%)
of patients satisfied at least one of the three MDA criteria. The
range in proportion of children achieving this state was smaller
than using CID criteria, ranging from 48% on the cJADAS to
61% using the Magni-Manzoni criteria (table 3). There was also
greater overlap between MDA criteria than CID with 68% of
children classified in MDA by all three criteria. The largest dis-
crepancy was for the Magni-Manzoni criteria, which does not
require use of the PGE score in oligoarticular JIA (figure 1D).
In accordance, median PGE scores were higher in patients in
MDA only on the Magni-Manzoni criteria compared with the
JADAS10 (2.9 cm, IQR 2.0–5.0 cm vs 0.2 cm, IQR 0.0–0.8)
(table 4).
The frequency of CID and MDA in each ILAR subtype
A similar pattern across outcome criteria was seen across all
ILAR categories, with patients achieving no active joints more
frequently than MDA, CID on JADAS and CID on Wallace’s
preliminary criteria, respectively (figure 2). However, achieve-
ment of the most stringent composite criteria was achieved most
frequently in the oligoarticular subtype (CID Wallace’s prelimin-
ary criteria: 29%, CID JADAS10 43%). Patients with systemic
JIA experienced large variation in their outcomes, achieving
fewer of the criteria sets when more information on systemic
features was taken into account. These children had high
Table 3 The frequency of CID and MDA using complete case and multiple imputation analyses
Outcome criteria
Primary outcome:
Percent in CID/MDA following
imputations assuming data
MNAR (%; 95% CI) (n=1415)
Percent in CID/MDA using complete
case analysis
Percent in CID/MDA
using most extreme
scenarios (n=1415)
Per cent (%)
How many children
could be categorised Minimum Maximum
Single criteria for CID
Discharge from rheumatology as ‘well’ within the first year
following presentation
NA 1.7 1366 NA NA
Active joint count=0 67 (64 to 69) 48 1000 46 75
Physician global assessment=0 36 (33 to 39) 32 819 19 61
Parental global evaluation=0 28 (25 to 31) 23 928 15 50
Composite criteria for CID
Wallace’s preliminary criteria for CID 25 (22 to 28) 4.5 810 1.2 45
CID using JADAS10 38 (35 to 41) 5.1 688 2.5 54
CID using JADAS71 38 (35 to 41) 5.1 688 2.5 54
CID using cJADAS10 38 (35 to 42) 26 880 15 54
Composite criteria for MDA
MDA using JADAS10 53 (49 to 56) 13 522 5.0 68
MDA using JADAS71 53 (49 to 56) 13 522 5.0 68
MDA using cJADAS10 48 (45 to 51) 35 807 20 63
MDA criteria (Magni-Manzoni) 61 (58 to 64) 47 740 25 73
Cumulative achievement
Any single/composite CID or MDA* 72 (68 to 74) 56 1212 48 89
Any composite CID 42 (38 to 45) 25 1020 18 76
Any composite MDA 65 (62 to 68) 45 859 27 78
*Not including discharged ‘well’.
CID, clinically inactive disease; cJADAS, JADAS excluding erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease Activity Score; MDA, minimal disease activity; MNAR,
missing-not-at-random; NA, not available.
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achievement of no active joints (78%), but only 14% achieved
CID on Wallace’s preliminary criteria (see figure 2 and online
supplementary table S1).
DISCUSSION
Since the success of treat-to-target approaches in RA,17 18
similar strategies in JIA have been considered.19–22 However,
many published and investigator-defined targets have been used
across research.9 23 24 The current study highlights that even
published targets intended to capture the same construct iden-
tify different groups of children. Results from studies using dif-
ferent outcome criteria therefore cannot be compared directly.
In addition, if used as targets in clinical practice, using different
targets may result in overtreatment or undertreatment.
Achievement of CID and MDA varied greatly between criteria
in this cohort. Broad achievement of CID was around 30% and
MDA around 50%. This indicates a significant level of ongoing
disease symptoms at 1 year following initial presentation. Using
Wallace’s preliminary criteria, only 25% children achieved CID.
Higher estimates have been gained from other inception cohorts
within similar timeframes in the literature, with estimates of
45% within 1 year25 and 53% at 18 months.26 These higher esti-
mates are likely artefacts of measuring ever achievement in the
former study and not including children with polyarticular JIA
in the latter. Estimates of CID from the literature not using
Wallace’s preliminary criteria vary widely from 19%27 to 60%.28
Estimates of CID using newer criteria, including cut-offs on
the JADAS6 or cJADAS7 have not yet been published from other
inception cohorts. The current study found that the JADAS and
cJADAS CID cut-offs have high overlap, capturing almost iden-
tical groups of children. Where discordant, children only in
CID on the cJADAS had substantially higher ESR (42 vs 0 mm/
hour). That so few children presented with low symptomatology
but high inflammatory markers suggests a non-rheumatological
cause of high ESR, such as recent infection. The cJADAS was
designed to be more feasible in clinical practice compared with
JADAS, since ESR is not required.29 Since overlap between
these criteria was excellent and complete data were available in
20% more patients in the three variable cJADAS, the current
data support the use of cJADAS in preference to JADAS when
assessing CID. However, overlap between the JADAS and
Wallace’s preliminary criteria was poorer.
Lower overlap between the physician and parent global assess-
ments, and between Wallace’s preliminary criteria and the
JADAS criteria, may reflect the different components included
within each criteria and challenges the concept of what consti-
tutes inactive or minimal disease in JIA. Unlike Wallace’s prelim-
inary criteria, the JADAS and cJADAS include a subjective
parent (child)-assessed component (table 1). Overlap between
this and either JADAS set of criteria was only 44% (figure 1).
The minimally different median scores on the PGA for children
in CID only on Wallace’s preliminary criteria (0.0 cm) versus
only the JADAS10 (0.2 cm) suggest that clinicians may not mark
children at exactly zero, even on resolution of active disease. In
this study, scores were recorded on paper and transcribed into
the study database. With a move to online data capture and elec-
tronic medical records, this issue may resolve if relating to tran-
scription errors, but equally it may be that clinicians did not feel
they could mark at exactly zero. These issues are resolved when
using criteria such as the JADAS or cJADAS. Since CID on these
numeric rating scales is defined as any score lower or equal to
one, minimal scores above zero will be captured as part of the
spectrum of CID. However, the substantial difference in the
PGE (medians 2.2 and 0.0 cm, respectively) suggests a marked
difference in global well-being for children identified as CID on
the different criteria. The patient global assessment has been
Table 4 Comparison of disease activity where CID/MDA criteria were discordant
Discordant criteria N
Component
Active joint count
(median, IQR)
Physician global (cm)
(median, IQR)
Parental global (cm)
(median, IQR)
Percent with
systemic features (%) ESR (median, IQR)
Zero active joints vs zero on physician global
Zero active joints only 465 0 (0, 0) 0.5 (0.2, 1.2) 0.6 (0.1, 2.5) 4 8 (3, 18)
Zero on physician global only 54 1 (1, 1) 0.0 (0.0, 0.0) 0.5 (0.0, 2.1) 1 7 (3, 16)
Zero on both 474 0 (0, 0) 0.0 (0.0, 0.0) 0.1 (0.0, 0.8) 2 7 (3, 16)
Zero on physician vs parental global
Zero on physician global only 274 0 (0, 0) 0.0 (0.0, 0.0) 0.8 (0.2, 2.2) 2 3 (1, 7)
Zero on parental global only 234 0 (0, 1) 0.5 (0.2, 1.5) 0.0 (0.0, 0.0) 4 8 (4, 20)
Zero on both 161 0 (0, 0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 2 7 (3, 17)
CID Wallace’s preliminary criteria vs JADAS10
CID only Wallace’s preliminary criteria 93 0 (0, 0) 0.0 (0.0, 0.0) 2.2 (1.4, 4.4) 0 7 (3, 20)
CID only JADAS10 327 0 (0, 0) 0.2 (0.1, 0.4) 0.0 (0.0, 0.3) 4 6 (3, 12)
CID on both 213 0 (0, 0) 0.0 (0.0, 0.0) 0.1 (0.0, 0.3) 0 6 (2, 11)
CID JADAS10 vs cJADAS10
CID only on JADAS 0 – – – – –
CID only on cJADAS 3 0 (0, 0) 0.1 (0.0, 0.1) 0.1 (0.0, 0.3) 2 42 (34, 65)
CID on both 541 2 6 (2, 11)
MDA Magni-Manzoni vs JADAS10
MDA Magni-Manzoni only 149 0 (0, 0) 0.4 (0.0, 1.5) 2.9 (2.0, 5.0) 4 12 (5, 35)
MDA JADAS10 only 69 1 (1, 1) 0.3 (0.0, 0.6) 0.2 (0.0, 0.8) 5 6 (3, 12)
MDA on both 704 0 (0, 0) 0.0 (0.0, 0.3) 0.1 (0.0, 0.5) 2 7 (3, 12)
CID, clinically inactive disease; cJADAS, clinical JADAS; ESR, erythrocyte sedimentation rate; JADAS10, Juvenile Arthritis Disease Activity Score weighed to 10 joints; MDA, minimal disease
activity.
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shown to be driven in large part by ongoing pain.30 31 A feature
of JIA for a subset of children is the resolution of inflammation
with persistent pain symptoms, which patients themselves have
considered as active disease.32 While it is not possible to disen-
tangle pain, related to inflammation or not, from other active
disease symptoms using patient and parent global assessments,
any symptom that patients themselves feel relate to their disease
and require treatment via rheumatology should be treated as
such. In concordance, applying criteria such as the JADAS and
cJADAS which assess both inflammation and a patient’s assess-
ment of their disease may identify children with persistent
chronic pain independent of joint inflammation, particularly in
cases where scores are high despite the absence of active joints.
These children could then be targeted for alternative pain man-
agement strategies, for example, psychological support.
ILAR subtype-specific estimates provided some evidence that
patients with the less common subtypes are less likely to achieve
CID. This may be a result of higher PGA ratings for patients
with extra-articular features, including exanthema and macro-
phage activation syndrome for systemic JIA. For the majority of
criteria, oligoarticular JIA was the most favourable disease
course with RF-positive polyarticular the least favourable,
corroborating existing evidence.25 33–35 Patients with systemic
disease had the largest variation in outcome estimates (14%–
78%), which was largely driven by components of the individ-
ual composite criteria; when more information on systemic
features was included, fewer children in this subtype achieved
the outcome. This trend indicates that systemic features should
be included when assessing CID or MDA in children with
systemic JIA and highlights the importance of both physician-
reported and patient/parent-reported global scores. Since no sets
of criteria included in this analysis explicitly captured enthesitis
or psoriasis, it remains to be seen whether the inclusion of cri-
teria based on these features improves the measurement of CID
in affected children.
The current study benefits from studying a large inception
cohort of patients across all ILAR subtypes of JIA. It highlights
the difference in disease states being targeted by clinicians and
used as outcomes in research. Going forward, the introduction
of composite measures and treatment targets into the clinical
setting have the potential to streamline the collection of clinical
data, enabling comparisons from one visit to the next and
between different centres. Further work is indicated to establish
the feasibility, acceptability and utility of composite scores and
treatment targets in clinical practice as well as in the context of
clinical trials to improve future data capture and completeness.
This study also provides an update on the frequency of CID and
remission in a contemporary JIA cohort. This information is
very important in the clinical setting, helping clinicians to realis-
tically manage patient expectations at presentation. As the
primary outcome was overlap between the published definitions,
which is unlikely to change over time, multiple time points were
not assessed. A previous study in this cohort, however, assessed
achievement of CID on the cJADAS71 across children with JIA
who initially presented to paediatric rheumatology between
2001 and 2011. They reported no significant increase in CID
achievement for children presenting in later years, despite a
wider variety of biological availability and a culture of more
aggressive treatment strategies.21 36
Limitations of the current study include that CID criteria
were applied to ILAR categories in which they are not validated:
namely systemic, enthesitis-related and psoriatic JIA. However,
the majority of previous studies have applied CID criteria in
their entire cohort including all categories.37–41 Therefore, to
assess the same disease state as applied in existing literature and
allow comparisons across all outcomes, the criteria were applied
to all JIA subtypes. As a consequence, current estimates may
overestimate the frequency of CID in children with persistent
systemic manifestations, enthesitis or psoriasis but no active
joint inflammation. Since these features are relatively rare, esti-
mates across the entire cohort were likely only marginally
Figure 1 Per cent patient overlap between outcome criteria. (A) Zero
on the PGA versus PGE, (B) CID JADAS10 versus cJADAS10, (C) CID
Wallace’s preliminary criteria versus JADAS10 and (D) MDA Magni-
Manzoni, JADAS10 and cJADAS10. For each figure, percentages are out
of all children who satisfied at least one of the criteria displayed. ESR,
erythrocyte sedimentation rate; cJADAS: clinical JADAS excluding ESR;
CID, clinically inactive disease; JADAS10, Juvenile Arthritis Disease
Activity Score in 10 joints; MDA, minimal disease activity.
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affected by their inclusion and these features are at least partially
reflected in physician and parental global scores. ILAR subtype-
specific definitions of CID may be of value in the future.
In this study, all items were captured as part of routine care
and not specifically within the setting of a clinical trial or study,
and many of the criteria included were not designed for a busy
clinical setting.42 The capture of these items in routine clinical
care of JIA vary greatly between clinical settings and composite
measures of disease activity were not routinely collected in UK
practice during the time of data capture in this study. This is
reflected in part by the amounts of missing data, a common
observation in ‘real-world’ research studies. The volume of
missing data was particularly high for composite measures,
where multiple elements were often not collected routinely. We
account for these missing data using a number of assumptions
and multiple imputation. Estimates using complete case analyses
were substantially lower than after imputation, partly due to
children with active disease being easier to classify in the com-
plete case analysis (see online supplementary material). The
majority of data missing were for laboratory measures, with
only 20% of children having ESR recorded at 1 year, reflecting
that children who are well may not have blood tests. Fantini
et al also reported that patients lost to follow-up had greater
remission rates than those present at follow-up.33 These trends
likely biased complete case estimates towards a greater propor-
tion of children with ongoing disease activity.
The frequency of remission according to the 2011 ACR pre-
liminary criteria8 could not be calculated in the current study.
This set of criteria requires information on morning stiffness,
which is notoriously difficult to determine in young children
and which was not collected as part of CAPS. International con-
sensus should be reached about a minimal core data set for both
observational and interventional research. This would aid moni-
toring of the JIA disease course and response to therapies, and
also aid comparability between clinical research studies. Where
feasible, future work should compare the frequency of achieving
the CID on the ACR 2011 preliminary criteria, with the states
highlighted in the current study.
Finally, this study highlights that published definitions of CID
and MDA identify distinctly different groups of children. While
the cJADAS10 cut-offs are more feasible to apply in clinical prac-
tice and appear to capture a greater picture of active JIA compared
with Wallace’s preliminary criteria, this study does not provide
data to support which measure is optimal in terms of long-term
outcomes. Future studies should compare long-term outcomes fol-
lowing early achievement of these measures to provide evidence
for a potential aim for treat-to-target approaches. Currently, there
are no recommendations for optimal treat-to-target strategies and
as such, these strategies are not common practice.
CONCLUSION
In a large inception cohort, a large proportion of patients with
JIA had evidence of persistent disease activity 1 year following
first presentation to paediatric or adolescent rheumatology.
However, the estimates of these disease states differed widely
based on which set of criteria was applied, many of which were
not disease subtype-specific. These differences highlight that the
same child could be classified as ‘in CID’ or having active
disease at the same time point between clinicians or hospitals.
Future work needs to explore which treatment target predicts
better long-term prognoses in JIA.
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